Literature DB >> 31055957

Discontinuation of Direct Oral Anticoagulants in Response to Attorney Advertisements: Data From the FDA Adverse Event Reporting System.

Mohamed Mohamoud, Saharat Patanavanich, Page Crew, Lynda McCulley, Monica Munoz, Cindy Kortepeter, S Christopher Jones, Daniel Woronow, Gerald Dal Pan.   

Abstract

Entities:  

Year:  2019        PMID： 31055957      PMCID： PMC8919214          DOI： 10.1177/1060028019849664

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN： 1060-0280            Impact factor:   3.154


× No keyword cloud information.
  5 in total

1.  Association of Attorney Advertising and FDA Action with Prescription Claims: A Time Series Segmented Regression Analysis.

Authors:  Elizabeth C Tippett; Brian K Chen
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.606

2.  Medical Advice from Lawyers: A Content Analysis of Advertising for Drug Injury Lawsuits.

Authors:  Elizabeth Tippett
Journal:  Am J Law Med       Date:  2015

3.  Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Authors:  Manesh R Patel; Anne S Hellkamp; Yuliya Lokhnygina; Jonathan P Piccini; Zhongxin Zhang; Surya Mohanty; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Richard C Becker; Christopher C Nessel; Scott D Berkowitz; Robert M Califf; Keith A A Fox; Kenneth W Mahaffey
Journal:  J Am Coll Cardiol       Date:  2013-02-12       Impact factor: 24.094

4.  Patient perception of transvaginal mesh and the media.

Authors:  Michelle Elaine Koski; Jennifer Chamberlain; James Rosoff; Taylor Vaughan; Melissa R Kaufman; Jack C Winters; Eric S Rovner
Journal:  Urology       Date:  2014-09       Impact factor: 2.649

5.  A Medwatch review of reported events in patients who discontinued rivaroxaban (XARELTO) therapy in response to legal advertising.

Authors:  Paul Burton; W Frank Peacock
Journal:  HeartRhythm Case Rep       Date:  2016-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.